Carboplatin‐induced regression of an optic pathway tumor in a child with neurofibromatosis

Joel Charrow*, Robert H Listernick, Mark J. Greenwald, Lakshmi Das, Mary Ann Radkowski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Optic pathway tumors are common in children with neurofibromatosis‐1 (NF‐1). The optimal management of these tumors is unknown, particularly when the optic chiasm and other brain structures are involved. We report the dramatic response to carboplatin in a 10‐year‐old girl with NF‐1 and a progressive optic pathway tumor. Tumor shrinkage was accompanied by striking improvement in visual fields, return of color discrimination, and marked improvement in visual acuity. No significant toxicity was observed. One year following completion of chemotherapy the glioma remains as small or smaller than it was at the conclusion of therapy, and there has been no deterioration of vision. Carboplatin is a promising agent for the treatment of optic pathway tumors in children with NF‐1. © 1993 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)680-684
Number of pages5
JournalMedical and Pediatric Oncology
Issue number9
StatePublished - Jan 1 1993


  • carboplatin
  • neurofibromatosis‐1
  • optic glioma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research


Dive into the research topics of 'Carboplatin‐induced regression of an optic pathway tumor in a child with neurofibromatosis'. Together they form a unique fingerprint.

Cite this